Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based Chlamydia abortus Vaccine

Efficacious vaccines are needed to control genital chlamydial diseases in humans and the veterinary industry. We previously reported a C. abortus (Cab) vaccine comprising recombinant Vibrio cholerae ghosts (rVCG) expressing the conserved and immunogenic N-terminal region of the Cab polymorphic membr...

Full description

Bibliographic Details
Main Authors: Shakyra Richardson, Fnu Medhavi, Tayhlor Tanner, Stephanie Lundy, Yusuf Omosun, Joseph U. Igietseme, Darin Carroll, Francis O. Eko
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.698737/full
id doaj-fbcb86b83c874200944e0c4ab1d744fd
record_format Article
spelling doaj-fbcb86b83c874200944e0c4ab1d744fd2021-06-24T06:10:26ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-06-011210.3389/fimmu.2021.698737698737Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based Chlamydia abortus VaccineShakyra Richardson0Fnu Medhavi1Tayhlor Tanner2Stephanie Lundy3Yusuf Omosun4Joseph U. Igietseme5Darin Carroll6Francis O. Eko7Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, United StatesDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, United StatesDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, United StatesDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, United StatesDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, United StatesNational Center for Emerging Zoonotic and Infectious Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, GA, United StatesNational Center for Emerging Zoonotic and Infectious Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, GA, United StatesDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, United StatesEfficacious vaccines are needed to control genital chlamydial diseases in humans and the veterinary industry. We previously reported a C. abortus (Cab) vaccine comprising recombinant Vibrio cholerae ghosts (rVCG) expressing the conserved and immunogenic N-terminal region of the Cab polymorphic membrane protein D (rVCG-Pmp18.1) protein that protected mice against intravaginal challenge. In this study, we investigated the immunomodulatory effect of the hematopoietic progenitor activator cytokine, Fms-like tyrosine kinase 3-ligand (FL) when co-administered with the rVCG-Pmp18.1 vaccine as a strategy to enhance the protective efficacy and the potential mechanism of immunomodulation. Groups of female C57BL/6J mice were immunized and boosted twice intranasally (IN) with rVCG-PmpD18.1 with and without FL or purified rPmp18.1 or rVCG-gD2 (antigen control) or PBS (medium) per mouse. The results revealed that co-administration of the vaccine with FL enhanced antigen-specific cellular and humoral immune responses and protected against live Cab genital infection. Comparative analysis of immune cell phenotypes infiltrating mucosal and systemic immune inductive tissue sites following immunization revealed that co-administration of rVCG-Pmp18.1 with FL significantly enhanced the number of macrophages, dendritic and NK cells, γδ and NK T cells in the spleen (systemic) and iliac lymph nodes (ILN) draining the genital tract (mucosal) tissues compared to rVCG-Pmp18.1 alone. Furthermore, FL enhanced monocyte infiltration in the ILN, while CD19+ B cells and CD4+ T cells were enhanced in the spleen. These results indicate that the immunomodulatory effect of FL is associated with its ability to mobilize innate immune cells and subsequent activation of robust antigen-specific immune effectors in mucosal and systemic lymphoid tissues.https://www.frontiersin.org/articles/10.3389/fimmu.2021.698737/fullChlamydia abortusPmp18Dvaccine deliveryFlt3Ladjuvant
collection DOAJ
language English
format Article
sources DOAJ
author Shakyra Richardson
Fnu Medhavi
Tayhlor Tanner
Stephanie Lundy
Yusuf Omosun
Joseph U. Igietseme
Darin Carroll
Francis O. Eko
spellingShingle Shakyra Richardson
Fnu Medhavi
Tayhlor Tanner
Stephanie Lundy
Yusuf Omosun
Joseph U. Igietseme
Darin Carroll
Francis O. Eko
Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based Chlamydia abortus Vaccine
Frontiers in Immunology
Chlamydia abortus
Pmp18D
vaccine delivery
Flt3L
adjuvant
author_facet Shakyra Richardson
Fnu Medhavi
Tayhlor Tanner
Stephanie Lundy
Yusuf Omosun
Joseph U. Igietseme
Darin Carroll
Francis O. Eko
author_sort Shakyra Richardson
title Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based Chlamydia abortus Vaccine
title_short Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based Chlamydia abortus Vaccine
title_full Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based Chlamydia abortus Vaccine
title_fullStr Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based Chlamydia abortus Vaccine
title_full_unstemmed Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based Chlamydia abortus Vaccine
title_sort cellular basis for the enhanced efficacy of the fms-like tyrosine kinase 3 ligand (fl) adjuvanted vcg-based chlamydia abortus vaccine
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2021-06-01
description Efficacious vaccines are needed to control genital chlamydial diseases in humans and the veterinary industry. We previously reported a C. abortus (Cab) vaccine comprising recombinant Vibrio cholerae ghosts (rVCG) expressing the conserved and immunogenic N-terminal region of the Cab polymorphic membrane protein D (rVCG-Pmp18.1) protein that protected mice against intravaginal challenge. In this study, we investigated the immunomodulatory effect of the hematopoietic progenitor activator cytokine, Fms-like tyrosine kinase 3-ligand (FL) when co-administered with the rVCG-Pmp18.1 vaccine as a strategy to enhance the protective efficacy and the potential mechanism of immunomodulation. Groups of female C57BL/6J mice were immunized and boosted twice intranasally (IN) with rVCG-PmpD18.1 with and without FL or purified rPmp18.1 or rVCG-gD2 (antigen control) or PBS (medium) per mouse. The results revealed that co-administration of the vaccine with FL enhanced antigen-specific cellular and humoral immune responses and protected against live Cab genital infection. Comparative analysis of immune cell phenotypes infiltrating mucosal and systemic immune inductive tissue sites following immunization revealed that co-administration of rVCG-Pmp18.1 with FL significantly enhanced the number of macrophages, dendritic and NK cells, γδ and NK T cells in the spleen (systemic) and iliac lymph nodes (ILN) draining the genital tract (mucosal) tissues compared to rVCG-Pmp18.1 alone. Furthermore, FL enhanced monocyte infiltration in the ILN, while CD19+ B cells and CD4+ T cells were enhanced in the spleen. These results indicate that the immunomodulatory effect of FL is associated with its ability to mobilize innate immune cells and subsequent activation of robust antigen-specific immune effectors in mucosal and systemic lymphoid tissues.
topic Chlamydia abortus
Pmp18D
vaccine delivery
Flt3L
adjuvant
url https://www.frontiersin.org/articles/10.3389/fimmu.2021.698737/full
work_keys_str_mv AT shakyrarichardson cellularbasisfortheenhancedefficacyofthefmsliketyrosinekinase3ligandfladjuvantedvcgbasedchlamydiaabortusvaccine
AT fnumedhavi cellularbasisfortheenhancedefficacyofthefmsliketyrosinekinase3ligandfladjuvantedvcgbasedchlamydiaabortusvaccine
AT tayhlortanner cellularbasisfortheenhancedefficacyofthefmsliketyrosinekinase3ligandfladjuvantedvcgbasedchlamydiaabortusvaccine
AT stephanielundy cellularbasisfortheenhancedefficacyofthefmsliketyrosinekinase3ligandfladjuvantedvcgbasedchlamydiaabortusvaccine
AT yusufomosun cellularbasisfortheenhancedefficacyofthefmsliketyrosinekinase3ligandfladjuvantedvcgbasedchlamydiaabortusvaccine
AT josephuigietseme cellularbasisfortheenhancedefficacyofthefmsliketyrosinekinase3ligandfladjuvantedvcgbasedchlamydiaabortusvaccine
AT darincarroll cellularbasisfortheenhancedefficacyofthefmsliketyrosinekinase3ligandfladjuvantedvcgbasedchlamydiaabortusvaccine
AT francisoeko cellularbasisfortheenhancedefficacyofthefmsliketyrosinekinase3ligandfladjuvantedvcgbasedchlamydiaabortusvaccine
_version_ 1721361628671246336